Essec\Faculty\Model\Contribution {#2237
#_index: "academ_contributions"
#_id: "16227"
#_source: array:26 [
"id" => 16227
"slug" => "16227-cost%e2%80%90effectiveness-analysis-of-second%e2%80%90line-lisocabtagene-maraleucel-in-the-treatment-of-refractory-or-relapsed-large-b%e2%80%90cell-lymphoma"
"yearMonth" => "2026-02"
"year" => 2026
"title" => "Cost‐Effectiveness Analysis of Second‐Line Lisocabtagene Maraleucel in the Treatment of Refractory or Relapsed Large B‐Cell Lymphoma"
"description" => "THIEBLEMONT, C., COLRAT, F., SELLAMI, R., SIVIGNON, M., PETEL, A., BRANCHOUX, S. et DE POUVOURVILLE, G. (2026). Cost‐Effectiveness Analysis of Second‐Line Lisocabtagene Maraleucel in the Treatment of Refractory or Relapsed Large B‐Cell Lymphoma. <i>European Journal of Haematology</i>."
"authors" => array:7 [
0 => array:3 [
"name" => "DE POUVOURVILLE Gérard"
"bid" => "B00072308"
"slug" => "de-pouvourville-gerard"
]
1 => array:1 [
"name" => "Thieblemont Catherine"
]
2 => array:1 [
"name" => "Colrat Florian"
]
3 => array:1 [
"name" => "Sellami Rahma"
]
4 => array:1 [
"name" => "Sivignon Marine"
]
5 => array:1 [
"name" => "Petel Adrien"
]
6 => array:1 [
"name" => "Branchoux Sébastien"
]
]
"ouvrage" => ""
"keywords" => array:4 [
0 => "CAR-T"
1 => "cost- effectiveness analysis"
2 => "LBCL"
3 => "lisocabtagene maraleucel"
]
"updatedAt" => "2026-04-07 11:43:56"
"publicationUrl" => "https://doi.org/10.1111/ejh.70131"
"publicationInfo" => array:3 [
"pages" => ""
"volume" => ""
"number" => ""
]
"type" => array:2 [
"fr" => "Articles"
"en" => "Journal articles"
]
"support_type" => array:2 [
"fr" => "Revue scientifique"
"en" => "Scientific journal"
]
"countries" => array:2 [
"fr" => null
"en" => null
]
"abstract" => array:2 [
"fr" => """
Objectives: CAR-T cell therapies such as lisocabtagene maraleucel (liso-cel) have transformed the treatment of patients with second line primary refractory or early relapsed ≤ 12 months (R/R) large B-cell lymphoma (LBCL). The objective of this study was to assess the cost-effectiveness of liso-cel compared to standard of care (SOC) to treat R/R LBCL in France.\n
Methods: A 3-health-state model was developed to compare liso-cel to SOC over 20 years in France. Efficacy and safety were extrapolated from the TRANSFORM trial (NCT03575351), or DESCAR-T (registry of patients treated with a CAR-T in France).Costs were calculated using French-specific sources. Outcomes were quality-adjusted life years (QALY), life-years (LY), total costs, incremental cost-utility and cost-effectiveness ratios (ICUR, ICER). Probabilistic sensitivity analysis (PSA) was conducted to assess the robustness of the results.\n
Results: Liso-cel generated 5.7 QALY (6.4 LY) for a €265 907. SOC generated 4.4 QALY (5.1 LY) for €233 903. ICUR and ICER were estimated at €24 580/QALY and €23 464/LY gained versus SOC. PSA showed that liso-cel was more effective and more costly in 92% of the simulations.\n
Conclusions: Liso-cel is cost-effective versus SOC to treat R/R LBCL patients in France. Generation of long-term real-world data is needed in order to validate these findings.
"""
"en" => """
Objectives: CAR-T cell therapies such as lisocabtagene maraleucel (liso-cel) have transformed the treatment of patients with second line primary refractory or early relapsed ≤ 12 months (R/R) large B-cell lymphoma (LBCL). The objective of this study was to assess the cost-effectiveness of liso-cel compared to standard of care (SOC) to treat R/R LBCL in France.\n
Methods: A 3-health-state model was developed to compare liso-cel to SOC over 20 years in France. Efficacy and safety were extrapolated from the TRANSFORM trial (NCT03575351), or DESCAR-T (registry of patients treated with a CAR-T in France).Costs were calculated using French-specific sources. Outcomes were quality-adjusted life years (QALY), life-years (LY), total costs, incremental cost-utility and cost-effectiveness ratios (ICUR, ICER). Probabilistic sensitivity analysis (PSA) was conducted to assess the robustness of the results.\n
Results: Liso-cel generated 5.7 QALY (6.4 LY) for a €265 907. SOC generated 4.4 QALY (5.1 LY) for €233 903. ICUR and ICER were estimated at €24 580/QALY and €23 464/LY gained versus SOC. PSA showed that liso-cel was more effective and more costly in 92% of the simulations.\n
Conclusions: Liso-cel is cost-effective versus SOC to treat R/R LBCL patients in France. Generation of long-term real-world data is needed in order to validate these findings.
"""
]
"authors_fields" => array:2 [
"fr" => "Management"
"en" => "Management"
]
"indexedAt" => "2026-05-01T22:23:25.000Z"
"docTitle" => "Cost‐Effectiveness Analysis of Second‐Line Lisocabtagene Maraleucel in the Treatment of Refractory or Relapsed Large B‐Cell Lymphoma"
"docSurtitle" => "Articles"
"authorNames" => "<a href="/cv/de-pouvourville-gerard">DE POUVOURVILLE Gérard</a>, Thieblemont Catherine, Colrat Florian, Sellami Rahma, Sivignon Marine, Petel Adrien, Branchoux Sébastien"
"docDescription" => "<span class="document-property-authors">DE POUVOURVILLE Gérard, Thieblemont Catherine, Colrat Florian, Sellami Rahma, Sivignon Marine, Petel Adrien, Branchoux Sébastien</span><br><span class="document-property-authors_fields">Management</span> | <span class="document-property-year">2026</span>"
"keywordList" => "<a href="#">CAR-T</a>, <a href="#">cost- effectiveness analysis</a>, <a href="#">LBCL</a>, <a href="#">lisocabtagene maraleucel</a>"
"docPreview" => "<b>Cost‐Effectiveness Analysis of Second‐Line Lisocabtagene Maraleucel in the Treatment of Refractory or Relapsed Large B‐Cell Lymphoma</b><br><span>2026-02 | Articles </span>"
"docType" => "research"
"publicationLink" => "<a href="https://doi.org/10.1111/ejh.70131" target="_blank">Cost‐Effectiveness Analysis of Second‐Line Lisocabtagene Maraleucel in the Treatment of Refractory or Relapsed Large B‐Cell Lymphoma</a>"
]
+lang: "fr"
+"_score": 8.594821
+"_ignored": array:3 [
0 => "abstract.en.keyword"
1 => "abstract.fr.keyword"
2 => "description.keyword"
]
+"parent": null
}
